Peripheral T-Cell Reprogramming Characterized by Actin Remodeling and Suppressive Communication in Pembrolizumab-Resistant Lung Adenocarcinoma
Resistance to PD-1 blockade remains a major challenge in lung adenocarcinoma, and the systemic immune mechanisms underlying therapeutic failure are not fully understood. Peripheral blood provides a minimally invasive window to monitor immune remodeling; however, single-cell-level characterization of T-cell alterations associated with pembrolizumab resistance is still limited. Peripheral blood samples from lung adenocarcinoma patients treated with pembrolizumab were collected and stratified into response (CR/PR, n = 3) and nonresponse (SD/PD, n = 4) groups according to RECIST 1.1. Single-cell RNA sequencing was performed to profile immune cell composition and transcriptional states. hdWGCNA was applied to identify response-associated co-expression modules, CellChat was used to intercellular communication, and Monocle2 was employed to explore inferred T-cell state relationships. A total of 91,576 high-quality cells were analyzed. In pooled summaries, patients in the nonresponse group showed a higher relative proportion of CD4+ Treg cells and a lower relative proportion of CD8+ naïve T cells. Network analysis identified 23 module-related DEGs enriched in cytoskeleton- and adhesion-related functional categories. Cell–cell communication analysis predicted increased communication potential, including TGF-β and MIF pathways, and increased adhesion-type interactions such as ADGRE5–CD55 and ITGB2–ICAM1. Pseudotime analysis showed variation in cytoskeleton-associated gene expression (ACTB, ACTG1, PFN1, and S100A family genes) along the inferred trajectory, indicating variation in cytoskeleton-related transcriptional states. These findings associate pembrolizumab nonresponse with altered peripheral T-cell composition, cytoskeleton- and adhesion-related transcriptional programs, and predicted intercellular interactions, generating hypotheses for future functional and clinical validation.
Authors
- Meng‐Jia Li
- Lufeng Cheng (ORCID: https://orcid.org/0000-0003-3831-6214)
- Aerzu Mijiti
- Xuejun Xiao
- Nadira Dolkun (ORCID: https://orcid.org/0009-0000-9988-0711)
- Wumiti Xiefukaiti
- Zi-Hang Wang
- Qing-Mei Zhu
Institutions
- Xinjiang Medical University (CN)
- Xinjiang Institute of Materia Medica (CN)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3390/ijms272210410
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00